ArticleObstetrics and gynecology international2012
Epigenetics and breast cancers.
Article in Obstetrics and gynecology international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Natural Compounds and Breast Cancer: Chemo-Preventive and Therapeutic Capabilities of Chlorogenic Acid and Cinnamaldehyde.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Review
- Naringenin and Hesperidin as Promising Alternatives for Prevention and Co-Adjuvant Therapy for Breast Cancer.Antioxidants (Basel, Switzerland) · 2023Review
- Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases.International journal of molecular sciences · 2021Review
- The Aqueous Extract ofAdvances in pharmacological and pharmaceutical sciences · 2020Article
- Multiple gene-specific DNA methylation in blood leukocytes and colorectal cancer risk: a case-control study in China.Oncotarget · 2017Article
- DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification.EXCLI journal · 2016Article
- Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells.International journal of nanomedicine · 2016Article
- Genistein potentiates the effect of 17-beta estradiol on human hepatocellular carcinoma cell line.Advanced biomedical research · 2016Article
- Article
- Epigenetic marks in estrogen receptor alpha CpG island correlate with some reproductive risk factors in breast cancer.Molecular biology reports · 2014Article
- Genistein at maximal physiologic serum levels induces G0/G1 arrest in MCF-7 and HB4a cells, but not apoptosis.Journal of medicinal food · 2014Article
- In vitro evaluation of the efficacy of liposomal and pegylated liposomal hydroxyurea.Indian journal of clinical biochemistry : IJCB · 2014Article
- Evaluation of estrogenic, antiestrogenic and genotoxic activity of nemorosone, the major compound found in brown Cuban propolis.BMC complementary and alternative medicine · 2013Article
- Drug delivery of hydroxyurea to breast cancer using liposomes.Indian journal of clinical biochemistry : IJCB · 2013Article
- Hyperhomocysteinemia-Induced Monocyte Chemoattractant Protein-1 Promoter DNA Methylation by Nuclear Factor-κB/DNA Methyltransferase 1 in Apolipoprotein E-Deficient Mice.BioResearch open access · 2013Article
- Epigenetic influences in the aetiology of cancers arising from breast and prostate: a hypothesised transgenerational evolution in chromatin accessibility.ISRN oncology · 2013Article
- Potential clinical significance of ERβ ON promoter methylation in sporadic breast cancer.Medical oncology (Northwood, London, England) · 2013Article
- Modeling and prediction of cytotoxicity of artemisinin for treatment of the breast cancer by using artificial neural networks.SpringerPlus · 2013Article
- Implication of the Strand-Specific Imprinting and Segregation Model: IntegratingHereditary genetics : current research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several of the active compounds in foods, poisons, drugs, and industrial chemicals may, by epigenetic mechanisms, increase or decrease the risk of breast cancers. Enzymes that are involved in DNA methylation and histone modifications have been shown to be altered in several types of breast and other cancers resulting in abnormal patterns of methylation and/or acetylation. Hypermethylation at the CpG islands found in estrogen response element (ERE) promoters occurs in conjunction with ligand-bonded alpha subunit estrogen receptor (Erα) dimers wherein the ligand ERα dimer complex acts as a transcription factor and binds to the ERE promoter. Ligands could be 17-β-estradiol (E2), phytoestrogens, heterocyclic amines, and many other identified food additives and heavy metals. The dimer recruits DNA methyltransferases which catalyze the transfer of methyl groups from S-adenosyl-L-methionine (SAM) to 5'-cytosine on CpG islands. Other enzymes are recruited to the region by ligand-ERα dimers which activate DNA demethylases to act simultaneously to increase gene expression of protooncogenes and growth-promoting genes. Ligand-ERα dimers also recruit histone acetyltransferase to the ERE promoter region. Histone demethylases such as JMJD2B and histone methyltransferases are enzymes which demethylate lysine residues on histones H3 and/or H4. This makes the chromatin accessible for transcription factors and enzymes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.